AMLN Related Downgrades
-
BMO Capital Downgrades Amylin Pharmaceuticals (AMLN) to Market Perform
-
Baird Downgrades Amylin Pharmaceuticals (AMLN) to Neutral
-
Piper Jaffray Downgrades Amylin Pharmaceuticals (AMLN) to Neutral
-
Summer Street Downgrades Amylin Pharmaceuticals (AMLN) to Neutral
-
MKM Partners Downgrades Amylin Pharmaceuticals (AMLN) to Sell
-
BMO Capital Downgrades Amylin Pharmaceuticals (AMLN) to Market Perform
-
Hapoalim Securities Downgrades Amylin Pharmaceuticals (AMLN) to Sell
-
Piper Jaffray Upgrades Amylin (AMLN) to Overweight, Hapoalim Downgrades to Hold
-
Wave of Downgrades Hits Amylin, Alkermes, Eli Lilly (AMLN, ALKS, LLY)
-
Deutsche Bank Downgrades Amylin Pharmaceuticals (AMLN) to Hold; CR Letter on Bydureon - Launch in '13?
-
Collins Stewart Slaps a Sell Rating on Amylin (AMLN) Shares
-
BMO Capital Downgrades Amylin Pharmaceuticals (AMLN) to Underperform
-
Analysts Downgrade Sanofi Aventis Amid Long-Acting Insulin Concerns; Amylin Benefiting (SNY, AMLN, NVO)
-
Canaccord Adams Downgrades Amylin Pharmaceuticals (AMLN) to Sell
-
Morgan Stanley Downgrades Amylin Pharmaceuticals (AMLN) to Equalweight
-
Soleil Securities Downgrades Amylin Pharmaceuticals (AMLN) to Sell
-
Natixis Bleichroeder Downgrades Amylin Pharmaceuticals (AMLN) to Sell
-
Baird Downgrades Amylin Pharmaceuticals (AMLN) to Neutral
-
Jefferies Downgrades Amylin Pharmaceuticals (AMLN) to Hold
-
BMO Capital Downgrades Amylin Pharmaceuticals (AMLN) to Underperform
-
S&P Equity Research Downgrades Amylin Pharmaceuticals (AMLN) to Hold
-
Lehman Brothers downgrades Amylin Pharmaceuticals (AMLN) to Underweight
-
Wachovia downgrades Amylin Pharma (AMLN) to Market Perform
-
Lehman Brothers downgrades Amylin (AMLN) to Equal Weight
-
Thomas Weisel downgrades Amylin Pharma (AMLN) to Peer Perform
-
WR Hambrecht downgrades AMLN to Hold
-
First Albany Downgrades AMLN
-
Hearing Bear Steans Out Positive on AMLN
-
Smith Barney downgrades AMLN to Sell
Back to AMLN Stock Lookup
